• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    2/9/24 12:31:35 PM ET
    $ANL
    $ARQT
    $BTAI
    $CVM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANL alert in real time by email

    Gainers

    • Intelligent Bio Solutions (NASDAQ:INBS) shares moved upwards by 219.4% to $9.2 during Friday's regular session. The market value of their outstanding shares is at $6.6 million.
    • NanoString Technologies (NASDAQ:NSTG) shares rose 120.39% to $0.26. The market value of their outstanding shares is at $12.3 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) stock rose 28.18% to $1.41.
    • Lexaria Bioscience (NASDAQ:LEXX) shares increased by 21.05% to $2.3. The company's market cap stands at $24.2 million.
    • OKYO Pharma (NASDAQ:OKYO) shares moved upwards by 20.27% to $1.72. The company's market cap stands at $57.1 million.
    • Arcutis Biotherapeutics (NASDAQ:ARQT) shares increased by 20.08% to $6.84. The market value of their outstanding shares is at $662.5 million.

    Losers

    • Synlogic (NASDAQ:SYBX) stock decreased by 46.8% to $1.83 during Friday's regular session. The company's market cap stands at $16.8 million.
    • BioXcel Therapeutics (NASDAQ:BTAI) stock decreased by 37.59% to $2.34. The market value of their outstanding shares is at $70.0 million.
    • Renalytix (NASDAQ:RNLX) shares decreased by 29.81% to $0.38. The market value of their outstanding shares is at $18.9 million.
    • Syra Health (NASDAQ:SYRA) stock declined by 26.19% to $3.58. The company's market cap stands at $22.9 million.
    • Adlai Nortye (NASDAQ:ANL) shares fell 15.35% to $7.5. The market value of their outstanding shares is at $276.7 million.
    • CEL-SCI (AMEX:CVM) stock fell 15.09% to $2.42. The company's market cap stands at $120.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ANL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANL
    $ARQT
    $BTAI
    $CVM

    CompanyDatePrice TargetRatingAnalyst
    OKYO Pharma Limited
    $OKYO
    2/20/2026$7.00Overweight
    Piper Sandler
    Adlai Nortye Ltd.
    $ANL
    2/13/2026$16.00Neutral → Buy
    H.C. Wainwright
    OKYO Pharma Limited
    $OKYO
    12/8/2025$5.00Buy
    B. Riley Securities
    Arcutis Biotherapeutics Inc.
    $ARQT
    7/25/2025$18.00Neutral
    Goldman
    Adlai Nortye Ltd.
    $ANL
    6/2/2025Buy → Neutral
    H.C. Wainwright
    Arcutis Biotherapeutics Inc.
    $ARQT
    12/30/2024$19.00Buy
    H.C. Wainwright
    Adlai Nortye Ltd.
    $ANL
    9/4/2024$9.00Buy
    H.C. Wainwright
    Arcutis Biotherapeutics Inc.
    $ARQT
    8/28/2024$15.00Buy
    Jefferies
    More analyst ratings

    $ANL
    $ARQT
    $BTAI
    $CVM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis

    Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitisARQ-234 is a potent fusion-protein agonist of the CD200 receptor (CD200R), an immune-regulatory checkpoint involved in maintaining immune balance WESTLAKE VILLAGE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first participant has been enrolled in a Phase 1a/1b, double-blind, randomized, placebo-controlled study, ARQ-234-131, evaluating the s

    3/3/26 8:00:00 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference

    WESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston. Details for the Company's participation are as follows:     Fireside Chat: Monday, March 2, 2026 at 1:50 p.m. ET The webcast for this conference may be accessed via the "Events" section of the Company's website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference. About ArcutisAr

    2/27/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior yearReported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026Announced expansion of its dermatology sales force and, separately, the initiation of a targeted Arcutis commercialization effort for primary care and pediatric health care providersProduced positive op

    2/25/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANL
    $ARQT
    $BTAI
    $CVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kersten Geert R bought $200,001 worth of shares (38,023 units at $5.26), increasing direct ownership by 46% to 120,815 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    1/26/26 8:23:27 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Kersten Geert R bought $49,998 worth of shares (8,389 units at $5.96), increasing direct ownership by 11% to 81,794 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    12/5/25 8:48:04 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Bunka Christopher bought $25,241 worth of shares (27,500 units at $0.92) (SEC Form 4)

    4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

    7/30/25 5:12:54 PM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANL
    $ARQT
    $BTAI
    $CVM
    SEC Filings

    View All

    SEC Form 144 filed by Arcutis Biotherapeutics Inc.

    144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    3/2/26 6:21:36 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Arcutis Biotherapeutics Inc.

    144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    3/2/26 5:59:41 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Arcutis Biotherapeutics Inc.

    144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    3/2/26 5:25:46 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANL
    $ARQT
    $BTAI
    $CVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on OKYO Pharma with a new price target

    Piper Sandler initiated coverage of OKYO Pharma with a rating of Overweight and set a new price target of $7.00

    2/20/26 8:25:04 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adlai Nortye Ltd. upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Adlai Nortye Ltd. from Neutral to Buy and set a new price target of $16.00

    2/13/26 9:51:23 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on OKYO Pharma with a new price target

    B. Riley Securities initiated coverage of OKYO Pharma with a rating of Buy and set a new price target of $5.00

    12/8/25 8:35:27 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANL
    $ARQT
    $BTAI
    $CVM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

    12/19/23 3:40:08 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    12/15/23 5:01:31 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANL
    $ARQT
    $BTAI
    $CVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Leonard Keith R sold $997,195 worth of shares (39,272 units at $25.39) and exercised 39,272 shares at a strike of $8.28 (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    3/4/26 4:17:39 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Welgus Howard G. sold $256,518 worth of shares (10,000 units at $25.65), decreasing direct ownership by 17% to 49,744 units (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    3/4/26 4:16:29 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Edwards Larry Todd was granted 30,000 shares and sold $92,846 worth of shares (3,687 units at $25.18), increasing direct ownership by 18% to 175,178 units (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    3/3/26 8:43:03 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANL
    $ARQT
    $BTAI
    $CVM
    Financials

    Live finance-specific insights

    View All

    Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior yearReported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026Announced expansion of its dermatology sales force and, separately, the initiation of a targeted Arcutis commercialization effort for primary care and pediatric health care providersProduced positive op

    2/25/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year

    First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year  Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on January 2, 2026. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, no

    2/12/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference

    Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ETArcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026 WESTLAKE VILLAGE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Wednesday, February 25, 2026 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:3

    1/22/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANL
    $ARQT
    $BTAI
    $CVM
    Leadership Updates

    Live Leadership Updates

    View All

    OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

    Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to advance the company's development program in neuropathic corneal pain (NCP), leveraging urcosimod's FDA Fast Track designationThis appointment, following the recent CEO appointment, further strengthens OKYO's world-class ophthalmology leadership team LONDON and NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neur

    2/10/26 8:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

    Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the advancement of its commercial planning for IGALMI® in the at-home setting. As part of this, Mark Pavao, a commercial planning and launch advisor with more than 3

    1/12/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer

    Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board LONDON and NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announces that, effective immediately, Robert J. Dempsey will assume the role of Chief Executive Officer. Gary S. Jacob, Ph.D. will transition to Chief Development Officer and

    1/5/26 7:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANL
    $ARQT
    $BTAI
    $CVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

    SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    11/14/24 7:50:59 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc

    SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

    11/14/24 4:41:42 PM ET
    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care